145 related articles for article (PubMed ID: 30609169)
21. Visualization of corneal vascularization in peripheral hypertrophic subepithelial corneal opacification with OCT angiography.
Riedl JC; Wasielica-Poslednik J; Weyer-Elberich V; Vossmerbaeumer U; Pfeiffer N; Lisch W; Gericke A
Acta Ophthalmol; 2018 Dec; 96(8):e974-e978. PubMed ID: 29671946
[TBL] [Abstract][Full Text] [Related]
22. Late onset of persistent, deep stromal haze after corneal cross-linking in a patient with keratoconus.
Omary R; Shehadeh-Mashor R
Can J Ophthalmol; 2017 Apr; 52(2):e81-e83. PubMed ID: 28457313
[No Abstract] [Full Text] [Related]
23. Two cases of bilateral, stromal ring opacity of the cornea.
Caroline PJ; Melles GR
Cornea; 2001 Mar; 20(2):237-8. PubMed ID: 11248840
[No Abstract] [Full Text] [Related]
24. Allergic contact dermatitis caused by Mirvaso®, brimonidine tartrate gel 0.33%, a new topical treatment for rosaceal erythema.
Cookson H; McFadden J; White J; White IR
Contact Dermatitis; 2015 Dec; 73(6):366-7. PubMed ID: 26768997
[No Abstract] [Full Text] [Related]
25. Sensitization to and allergic contact dermatitis caused by Mirvaso(®) (brimonidine tartrate) for treatment of rosacea - 2 cases.
Bangsgaard N; Fischer LA; Zachariae C
Contact Dermatitis; 2016 Jun; 74(6):378-9. PubMed ID: 27133629
[No Abstract] [Full Text] [Related]
26. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
27. Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate.
Kasuya Y; Sano I; Makino S; Kawashima H
Case Rep Ophthalmol Med; 2020; 2020():4803651. PubMed ID: 32547800
[TBL] [Abstract][Full Text] [Related]
28. Sedative and physiological effects of brimonidine tartrate ophthalmic solution in healthy cats.
Ogata N; Kanda T; Kawahata M; Ichikawa T; Matsumoto Y; Morimitsu W; Nishino Y; Itoi T; Furumoto K
Vet Anaesth Analg; 2017 Sep; 44(5):1091-1100. PubMed ID: 28865952
[TBL] [Abstract][Full Text] [Related]
29. Double bubble with the big-bubble technique during deep anterior lamellar keratoplasty.
Wise S; Dubord P; Yeung SN
Int Ophthalmol; 2018 Jun; 38(3):1313-1316. PubMed ID: 28455642
[TBL] [Abstract][Full Text] [Related]
30. The adverse effect of perioperative brimonidine tartrate 0.2% on flap adherence and enhancement rates in laser in situ keratomileusis patients.
Walter KA; Gilbert DD
Ophthalmology; 2001 Aug; 108(8):1434-8. PubMed ID: 11470696
[TBL] [Abstract][Full Text] [Related]
31. Ocular changes in beagle dogs following oral administration of CGS 24565, a potential hypolipidemic agent.
Schiavo DM; Bentley P
Toxicol Sci; 2000 May; 55(1):189-94. PubMed ID: 10788573
[TBL] [Abstract][Full Text] [Related]
32. Three-month randomized trial of fixed-combination brinzolamide, 1%, and brimonidine, 0.2%.
Katz G; Dubiner H; Samples J; Vold S; Sall K
JAMA Ophthalmol; 2013 Jun; 131(6):724-30. PubMed ID: 23579344
[TBL] [Abstract][Full Text] [Related]
33. Deep corneal calcification after intensified treatment with artificial tears.
Zubicoa A; Iturralde O; Mozo Cuadrado M; Tabuenca Del Barrio L; Plaza Ramos P
J Fr Ophtalmol; 2020 Jan; 43(1):93-94. PubMed ID: 31837893
[No Abstract] [Full Text] [Related]
34. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
35. Chemical injury-induced corneal opacity and neovascularization reduced by rapamycin via TGF-β1/ERK pathways regulation.
Shin YJ; Hyon JY; Choi WS; Yi K; Chung ES; Chung TY; Wee WR
Invest Ophthalmol Vis Sci; 2013 Jul; 54(7):4452-8. PubMed ID: 23716625
[TBL] [Abstract][Full Text] [Related]
36. Topical brimonidine-assisted laser treatment for the prevention of therapy-related erythema and hyperpigmentation.
Lee SJ; Ahn GR; Seo SB; Park KY; Kim BJ; Nam Kim M
J Cosmet Laser Ther; 2019; 21(4):225-227. PubMed ID: 30235041
[TBL] [Abstract][Full Text] [Related]
37. Brimonidine gel for the treatment of persistent heliotrope rash in a patient with amyopathic dermatomyositis: a case report.
Navarrete-Dechent C; Manríquez JJ; del Puerto C; Vera-Kellet C
J Eur Acad Dermatol Venereol; 2016 Mar; 30(3):476-7. PubMed ID: 25443967
[No Abstract] [Full Text] [Related]
38. Increase in the OCT angiographic peripapillary vessel density by ROCK inhibitor ripasudil instillation: a comparison with brimonidine.
Chihara E; Dimitrova G; Chihara T
Graefes Arch Clin Exp Ophthalmol; 2018 Jul; 256(7):1257-1264. PubMed ID: 29520478
[TBL] [Abstract][Full Text] [Related]
39. Ocular perfusion pressure and visual field indice modifications induced by alpha-agonist compound (clonidine 0.125%, apraclonidine 1.0% and brimonidine 0.2%) topical administration. An acute study on primary open-angle glaucoma patients.
Costagliola C; Parmeggiani F; Ciancaglini M; D'Oronzo E; Mastropasqua L; Sebastiani A
Ophthalmologica; 2003; 217(1):39-44. PubMed ID: 12566871
[TBL] [Abstract][Full Text] [Related]
40. Drugs, Inflammation, and the Eye.
Cunningham ET; London NJ; Moorthy R; Garg SJ; Zierhut M
Ocul Immunol Inflamm; 2016; 24(2):125-7. PubMed ID: 27074544
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
